GlassScriptPhysician profile
Chinnavuth De Monteiro
NPI 1558392449
$21,289.69
in general payments reported to CMS, 2019-2025
61 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,641 · 2020: $3,407 · 2021: $4,033 · 2022: $2,895 · 2023: $3,282 · 2024: $3,221 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,245 · Education: $68.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,244.93 |
| Education | $68.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,420.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,098.68 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $2,087.58 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $1,587.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,563.54 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,486.84 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Novo Nordisk INC | $1,216.50 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,008.37 | 2020-2025 | Ubrelvy, Linzess, Viberzi |
| Bayer Healthcare Pharmaceuticals INC. | $952.13 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $670.31 | 2023-2025 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $634.06 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $501.53 | 2019-2025 | Xifaxan |
| Lundbeck LLC | $471.38 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $409.09 | 2019-2021 | |
| Amgen INC. | $394.54 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chinnavuth De Monteiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.